Katie Verb joins K&A as Vice President of Health and Reimbursement Policy

Katie Verb joins Kimbell & Associates as Vice President, Health and Reimbursement Policy.

Kimbell & Associates was founded in 1998 and currently represents over 86 clients in the healthcare industry. The firm’s expertise focuses on the executive and legislative branches of the U.S. federal government and specializes in providing strategic solutions to a select group of healthcare sector clients seeking creation, modification, or proper implementation of public law. Ms. Verb will be taking a leadership role in the health policy practice.

“Katie joins the firm with nearly 15 years of experience at life science companies, trade associations, and a patient advocacy organization. Her background in translating the business impact of policy, building consensus among multiple pharmaceutical companies, and working on behalf of patients will benefit all of our clients,” said Jeffrey Kimbell, founder of the firm. “Katie’s experience negotiating with CMS, developing cell and gene therapy policy solutions, and advocating for new 340B models will add additional expertise to our robust policy team.”

“Access and reimbursement policy is undergoing significant changes, between the implementation of negotiation in Medicare and proposals to import international pricing, and every part of the industry will need to adapt to the new environment. I am extremely excited to join a team of dedicated health policy and government affairs experts to support our clients as they navigate the evolving landscape,” said Verb.

Verb brings nearly 15 years of policy and advocacy experience, having led policy teams at multiple

pharmaceutical companies, developed policy solutions at PhRMA, and led the government affairs team advocating for patients at the Hemophilia Federation of America. Most recently Katie was the Head of Policy and Strategic Alliances at Bristol Myers Squibb (BMS). While at BMS, Katie was part of the team that negotiated the maximum fair price (MFP) with the Centers for Medicare and Medicaid Services (CMS) for BMS's drug subject to negotiation under the Inflation Reduction Act (IRA) in 2025 and led the policy strategy for the MFP negotiation in 2024. Katie led a team of federal and state policy subject matter experts responsible for ensuring coverage, access, and reimbursement across all public and private payers, as well as the Alliance team. Prior to joining BMS, Katie was the Head of Policy at Horizon Therapeutics and while at PhRMA, she was responsible for multiple issues including Medicare Part B, international reference pricing, and cell & gene therapy policy. Katie has a J.D. from Michigan State University College of Law and a Bachelor of Arts in Political Science from Loyola University Chicago.